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ABSTACT 
Objective: This study targets the inhibition of inflammatory mediators and the enhancement of gastrointestinal mucosa healing in ulcerative colitis 
in rats through sulfasalazine.  
Methods: Twenty four female albino rats were divided into 3 groups: normal control, colitis group (rats received 5% dextran sodium sulfate (DSS) 
in their drinking water for 7 d), sulfasalazine group (500 mg/kg/day was administrated orally one week ahead of DSS and parallel with its 
administration). The impact of sulfasalazine on intestinal inflammation was investigated via estimation of some inflammatory mediators, namely; 
serum Leucine rich α 2 Glycoprotein (LRG) as well as colon cAMP, Myloperoxidase (MPO) and TNF-α using ELISA technique as well as gene 
expression of Trefoil Factor 3 (TFF3), High mobility group box1 (HMGB1), Nuclear factor kappa B (NF-κB) and metalloproteinase-3 (MMP3) and 
miRNA-31 levels using RT-PCR. 
Results: Sulfasalazine substantially decreases the release of LRG, MPO and TNF-α and the expression of HMGB1, NF-κB, MMP3, TFF3 and miRNA31 at p≤ 
0.05 compared to colitis group in vivo. Moreover, Sulfasalazine significantly increases the colonic cAMP at p≤ 0.05 in groups of rats treated with DSS. 
Conclusion: Sulfasalazine has a protective effect on inflammatory bowel disease causing mucosal healing within the gastrointestinal tract. 
Additional studies are warranted to explore the molecular mechanism of sulfasalazine in ulcerative colitis and its clinical application. 
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INTRODUCTION 
Inflammatory bowel disease (IBD) comprises Crohn’s disease (CD) 
and ulcerative colitis (UC) is thought to be triggered by an irregular 
immune response resulting in a genetically prone host malfunction 
of the intestinal mucosal barrier against enteric bacteria [1]. The UC 
is based on the abnormal degradation of the intestinal mucosa due 
to various reasons; including genetic, environmental, microbial and 
immune inflammatory mediators [2]. The treatment priorities for 
IBDs include complication prevention, recovery and rehabilitation of 
nutritional deficiencies to improve the quality of life of patients. In the 
treatment of IBDs, the anti-inflammatory drugs include 
immunosuppressants, biological agents, antibiotics, and drugs to 
quash inflammatory responses and to alleviate symptoms [3]. A great 
number of cytokine abnormalities, including proinflammatory and 
immunoregulatory molecules have been described. In CD, interferon-
gamma (INF)-γ is generated by intestinal CD4+T cells, while 
interleukin 12 and 18 are released by mucosal macrophages [3].  
The most commonly used mouse models of colitis utilize dextran sodium 
sulfate (DSS), a chemical colitogen with anticoagulant properties, for 
disease induction. Due to its speed, reproducibility, usability, and 
management, the DSS colitis model is very popular in IBD research. 
Acute, chronic and relapsing models of intestinal inflammation can be 
accomplished by altering DSS concentration and administration [4]. 
Sulfasalazine, which consists of 5-aminosalicylate (5-ASA-active 
component) and sulfapyridine, demonstrated its induction efficacy 
and remission maintaining in mild to moderate UC [5]. Topical 5-
ASA is a member of distal disease [5]. ASA agents can have several 
anti-inflammatory effects, including inhibition of cyclooxygenase, 
lipoxygenase, B-cells and other inflammatory cytokines. 5-ASA has 
been shown to trigger the selective peroxisome proliferators-
activated receptor ligand-γ (PPAR-γ) which regulates cell 
proliferation and apoptosis [6]. It usually takes between 3 and 6 w 
for induction of remission in mild to moderately active UC [7]. So, 
the present research was therefore carried out to determine the 
pharmacological effects of sulfasalazine and the molecular 
mechanisms underlying these effects through measuring genetic 
expression of Trefoil Factor 3 (TFF3), High mobility group box1 
(HMGB1), Nuclear factor kappa B (NF-kB), Metalloproteinase-3 
(MMP3) and miRNA31 levels and some inflammatory mediators in 
DSS-caused ulcerative colitis experimentally in rats. 
MATERIALS AND METHODS 
Chemicals  
DSS (molecular weight: 36,000–50,000 Daltons), Sulfasalazine (purity ≥ 
98%), hexadecyltrimethylammonium bromide (HTAB), O-dianisidine 
hydrochloride and potassium phosphate buffer were bought from Sigma 
Aldrich (St. Louis, MO, USA). The remaining chemicals used in this study 
were of the analytical grade, maintained under standard conditions, and 
supplied by standard commercial providers. 
Animals 
This experiment was performed in conjunction with guidelines laid 
down by the Animal Care using ethical Committee, approval no 
20191120, Faculty of applied medical sciences, October 6 university. 
Adult female albino Wister rats weighing around 160±20 g were 
obtained from the Faculty of Veterinary Medicine, Cairo University 
(Cairo, Egypt). They were individually held in cages in an air-
conditioned room with a temperature of 23±2 ⁰C, 60% relative 
humidity, and an 8:00 a. m. to 8:00 p. m. light cycle. Every animal 
was reared on a normal diet (Dyets, Inc., Bethlehem, PA, USA) ad 
libitum during the acclimatization period, 
Experimental setup  
This experiment was performed to investigate Sulfasalazine’s 
protective effects against DSS-mediated ulcerative colitis in rats, and 
all the studied parameters have been repeated twice to ensure the 
reproducibility of the results. The animals were grouped into three, 
including eight animals each. 
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Group I: Normal control (was given 0.5 ml of autoclaved drinking 
water) 
Group II: was treated with DSS, 5.0% in autoclaved drinking water 
for 7 d [8]. 
Group III: was given sulfasalazine orally (500 mg/kg) in autoclaved 
drinking water in a single daily dosage for 7 d before induction of UC 
and 7 d parallel with DSS [9]. 
On the 15th 
The colon was subsequently excised and cleaned with ice-cold 
physiological saline from blood. Then, the tissue was dried between 
filter papers to absorb moisture. Colon tissues were homogenized in 
45 mmol potassium phosphate buffer (pH 6) solution that comprises 
0.5% hexadecyltrimethylammonium bromide (HTAB). The colon 
homogenates were exposed to 3 freezing/thawing cycles, sonication 
for 30 seconds and centrifugation at 20,000 × g for 20 min at 4 °C 
[10]. O-dianisidine hydrochloride 0.167 mg/ml and 0.3% H
d, all rats were sacrificed, at the completion of the study, 
blood was obtained and serum was freshly used to estimate LRG as 
well as Real time quantitative PCR (RT-qPCR) for TFF3, HMGB1, NF-
κB and MMP3.  
2O2
Biochemical assays  
 in 45 
mmol potassium phosphate buffer (pH 6.0) were applied to the 
supernatant. ELISA kit was obtained from Glory science Co., Ltd. 
(China) and used to assess the levels of TNF-α, cyclic AMP and MPO 
activity in colon tissue homogenate. 
The serum level of LRG was quantitatively estimated by ELISA using 
the Rat LRG Assay Kit–IBL, Code No. 27770. 
Colon TNF-α and cyclic AMP as well as myeloperoxidase (MPO, E. C. 
1.11.2.2) activity were quantitatively estimated by ELISA according 
to Kawakami et al. [11], El-Ashmawy et al. [12] and Krawisz et al. 
[13] respectively. Finally, the protein content of liver tissue was 
calculated [14]. 
miRNA-31 analysis using RT-qPCR  
Total RNA was extracted from myocardial tissue of rats from each group 
using Trizol reagent (Invitrogen, California, USA). The ultraviolet 
Spectrophotometer measured the concentration of extracted RNA 
(Agilent Technologies, CA, USA) and a gel imaging system analyzed the 
integrity of RNA (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Stem-
loop real-time RT-PCR was used to determine the expression of miRNA-




Reverse, 5′-GCCGCAGGCAAGATGCTGGC-3′.  
The 25 μl PCR reaction mixture consists of 1× SYBR premix Ex 
Taq mix (Takara), 2 μl RT products and 10 nM of both forward 
and reverse primer. Reactions were held on a 96-well plate at 95 
°C for 30 sec, followed by 45 cycles of 95 °C for 15 sec and 60 °C 
for 21 sec. Dissociation from 65 to 95 °C was conducted to 
confirm the specificity of the amplification products. The 
threshold cycle data were determined using second derivative 
max settings. U6 was used as an internal control to standardize 
target miRNA levels. The primers of stem loop RT and 
amplification primers of U6 were defined by Ribobio Co., Ltd., 
Guangzhou, China). 
Reverse transcription quantitative PCR (RT-qPCR) 
Total RNA has been isolated using a Qiagen extraction kit (Qiagen, 
USA) as stated by instructions of manufacture.  
cDNA synthesis 
The total RNA (0.5-2 μg) was used for cDNA conversion using high 
ability cDNA reverse transcription kit Fermentas, USA). 
Procedure 
Three μl of random primers were introduced to the 10 μl of RNA 
that was denatured for 5 min at 65 °C in the thermal cycler, the 
mixture of RNA primer was refrigerated to 4 °C and the master mix 
of cDNA was prepared as outlined in the kit instructions and was 
applied to each sample (table 1): 
 
Table 1: The cDNA master mix 
Component Volume 
First strand buffer 5 μl 
10 mmoldNTPs 2 μl 
RNase inhibitor [40 U/μl] 1 μl 
MMLV-RT enzyme [50 U/μl] 1 μl 
DEPC-treated water 10 μl 
 
The total volume of the master mix was 19 μl for each specimen. 
This was transferred to the 31μl RNA-primer mixture which results 
in 50 μl of cDNA. 
c) The last mixture was incubated in the programmed thermal cycler 
for one hour at 37 °C followed by deactivation of enzymes at 95 °C 
for 10 min, and finally cooled at 4 °C. Then, RNA was turned into 
cDNA. The converted cDNA was held at–20 °C. 
Real-time qPCR using SYBR green I 
Real-time qPCR amplification and analysis were carried out using an 
Applied Biosystem with software version 3.1 (StepOne™, USA). The 
qPCR assay and the primer sets (table 2) were optimized at the 
annealing temperature.  
 
Table 2: The primer sequence of the studied gene 
Trefoil factor 
3 (TFF3) 
Forward primer: 5’-TAATGCTGTTGGTGGTCCTG-3’ 
Reverse primer: 5’-CAGCCACGGTTGTTACACTG-3’ 
HMGB1 Forward: 5’-GCCTCGCGGAGGAAAATC-3’ 
Reverse: 5’-AAGTTTGCACAAAGAATGCATATGA-3’ 
NF-Κb Forward: 5’-GTGGAGGCATGTTCGGTAGTG-3’ 
Reverse: 5’-TCTTGGCACAATCTTTAGGGC-3’ 
MMP3 Forward: 5′-ACTCTACCACTCAGCCCAAGG-3′ 
Reverse: 5′-TCCAGAGAGTTAGACTTGGTGG-3′ 
Beta actin Forward 1T5′-1TATCACCATCTTCCAGGAGCG-1T3′ 
Reverse 1T5′-1TCCTGCTTCACCACCTTCTTG1T-3′ 
 
Preparation of the reaction master mix for Q-PCR 
1-For every sample, the following reagents and volumes were 
applied:  
Forward primer 1 μl, Reverse Primer 1 µl, Syber green mix 12.5 μl, 
cDNA template 5 μl, RNAse free water 5.5 μl. 
2-Running conditions for RT-PCR were as follows 
The cDNA was subjected to real-time PCR under the following 
conditions: 50 °C (2 min) (one cycle), 95 °C (15 sec), 60 °C (1 min), 
and 72 °C (1 min) (40 cycles) 
Calculation of Relative Quantification (RQ) (relative expression) 
The relative quantitation was calculated due to Applied Bio system 
software utilizing the following equation 
∆ Ct = Ct gene test–Ct endogenous control  
∆∆Ct = ∆Ct sample1–∆Ct calibrator  
RQ = Relative quantification = 2 P-∆∆Ct 
The RQ is the fold change compared to the calibrator (untreated 
sample) 
Histopathological examination 
Colon segments were fixed for 24 h in formalin, washed and 
dehydrated using serial alcohol dilution. The Specimen was washed 
in xylene, coated in paraffin wax and tissue blocks were cut at a 
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thickness of 4 mm using microtome (Leica RM2155, Germany). The 
tissue parts obtained were placed on glass slides, deparaffinized, 
stained with hematoxylin and eosin (HandE) and checked with a 
light microscope. All histopathological processing of specimens was 
performed by a trained researcher oblivious to the identity of the 
specimen being examined to prevent any prejudice. 
Statistical analysis 
All the data were statistically evaluated by SPSS/15 software. 
Hypothesis testing approaches included one-way analysis of 
variance (ANOVA) followed by the least significant difference (LSD) 
test. It was assumed that p values less than 0.05 would suggest 
statistical significance. All the findings were manifested as mean±SD 
for eight separate determinations. 
RESULTS 
Acute inflammation occurred in the rats with DSS, including signs of 
body weight loss, loose feces/watery diarrhea and fecal blood 
presence; all of these signs intensified at 7 d. 
Serum LRG and colonic MPO, TNF-α and cAMP 
DSS 5% significantly (P<0.01) increased the levels of serum leucine-
rich alpha-2-glycoprotein (LRG) as well as colon MPO and TNF-α 
relative to the control group. Treatment with sulfasalazine (500 
mg/kg) for 7 d before UC induction and parallel with DSS, showed 
significant (P<0.05) inhibition in level of LRG, MPO and TNF-α as 
compared with the DSS group (table 3). The colonic cAMP level was 
significantly (P<0.01) reduced in DSS administered group as 
compared with control animals. Treatment with sulfasalazine 
significantly elevated the level of colonic cAMP level (P<0.05) as 
compared with the DSS group (table 3). 
Genetic expression levels of TTF3, HMGB1, NF-KB and MMP3 
The present results showed that the gene expression of 
inflammatory mediators and tissue repair factor, TFF3 levels 
produced a significant (P<0.01) increase in DSS-induced ulcerative 
colitis when compared to control animals. Also, TFF3 was 
significantly (P<0.01) reduced in the sulfasalazine group relative to 
the DSS treated group (fig. 1). 
  
Table 3: Effect of oral administration of sulfasalazine on serum leucine-rich alpha-2-glycoprotein (LRG) as well as colon cyclic AMP, MPO 
and TNF-α in DSS induced ulcerative colitis in rats 
No. Groups Serum  
LRG (ng/ml) 
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DSS (5% in drinking 









Data shown are mean±standard deviation of the number of results within each therapy, Data followed by the same letter are not significantly 
different at P ≤ 0.05.  
 
 
Fig. 1: Effect of sulfasalazine on serum trefoil factor 3 (TFF3) in the different studied groups of rats. Representative bar diagram of three 
independent experiments are presented 
 
 
Fig. 2: Effect of sulfasalazine on serum high mobility group box-1 (HMGB1) in different studied groups of rats. Representative bar diagram 
of three independent experiments are presented 
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The results are expressed as fold increase or decrease considering 
the control one. Significance was done at p<0.05. a: significant 
versus control b: significant versus DSS (sample size is 8 rats in each 
group) 
The expression levels of serum HMGB1, nuclear factor-κB (NF-κB 
and MMP3 in the DSS group were higher than those in the control 
group (P<0.01). Sulfasalazine treatment significantly reduced the 
expression levels of HMGB1, NF-κB and MMP3 (P<0.05) as 
compared with the DSS group (fig. 2,3,4,5). 
The results are expressed as fold increase or decrease considering the 
control one. Significance was done at p<0.05. a: significant versus 
control, b: significant versus DSS (sample size is 8 rats in each group) 
 
 
Fig. 3: Effect of sulfasalazine on serum nuclear factor-κB (NF-κB) in different studied groups of rats. Representative bar diagram of three 
independent experiments are presented 
 
The results are expressed as fold increase or decrease considering 
the control one. Significance was done at p<0.05. a: significant 




Fig. 4: Effect of sulfasalazine on serum matrix metalloproteinase 3 (MMP 3) in the different studied groups of rats. Representative bar 
diagram of three independent experiments are presented 
 
The results are expressed as fold increase or decrease considering 
the control one. Significance was done at p<0.05. a: significant 




Fig. 5: An agarose gel electrophoresis shows PCR products of serum trefoil factor 3 (TFF3) (A), high mobility group box-1 (HMGB1) (B), 
nuclear factor-κB (NF-κB) (C), matrix metalloproteinase 3 (MMP 3) (D) and Beta actin in different studied groups as G1 stands for group I, 
G2 stands for group II and G3 stands for group III (sample size is 8 rats for each group) 
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Genetic expression level of miRNA-31 in colon 
The expression level of miRNA-31 was upregulated in colonic 
tissues treated with DSS by 3.3 times, compared to the normal 
group (P<0.01) (fig. 6). On the other hand, miRNA-31 expression 
level in sulfasalazine treated rat groups showed significant 




Fig. 6: Effect of sulfasalazine on colon miRNA 31 in the different studied groups of rats. Representative bar diagram of three independent 
experiments are presented 
The results are expressed as fold increase or decrease considering the control one. Significance was done at p<0.05. a: significant versus control, b: 
significant versus DSS (sample size is 8 rats in each group) 
 
Histopathological changes 
Colonic sections from control group revealed typical architecture of 
colon tissue (fig. 7 a).  
 
 
a) Normal Control: Normal architecture of the mucosa (x40) 
 
b) DSS colitis rats: Cryptitis, crept branching and distor tion (x100) 
 
c) Sulfasalazine treated group: Normal mucosa and mild 
glandular reparative changes (x40) 
Fig. 7: Photomicrographs of colon tissue sections (H and E) 
On the other hand, Colons of the DSS group indicated ulceration with 
inflammatory cell infiltration (fig. 7 b) However, colons of the 
sulfasalazine treated group displayed nearly normal histological 
structure (fig. 7 c) 
DISCUSSION  
Inflammatory Bowel Disease (IBD) is a gastrointestinal tract, chronic 
inflammatory condition. IBD has historically been classified into 
Crohn’s disease (CD) and ulcerative colitis (UC) [16]. Crohn’s disease 
and Ulcerative Colitis are distinguished by their clinical 
manifestations and pathogenic mechanisms they hypothesize [17]. 
UC is a relapsing chronic inflammatory condition that is confined to 
the colon and marked by bloody diarrhea during disease flares [18]. 
The CD is a chronic, segmental localized granulomatous disease that 
can affect from the mouth to the anus anywhere in the entire 
gastrointestinal tract. Ulcerative Colitis and Crohn’s disease can 
occur at any age, yet most patients are diagnosed during their third 
decade of life [18]. 
The present study verified the comparative evaluation of 
sulfasalazine’
Administration of sulfasalazine caused anti-inflammatory effects, 
including decreased serum LRG, MPO and TNF-α levels, among the 
DSS-treated groups. The present results were confirmed by the 
results of Mi et al. [9]. 
s pharmacological efficacy in the rat model of UC. As 
shown in fig. 7 DSS group demonstrated inflammatory cell 
infiltration edema and lining mucosal epithelium desquamation. 
These findings may be due to the direct lethal effect of DSS resulting 
in breakdown of the mucosal epithelial barrier. Our findings were in 
line with other earlier reports [19]. Treatment with sulfasalazine 
ameliorated histopathological changes. As shown in table 1, the DSS 
control group displayed significantly reduced cAMP and increased 
LRG, MPO and TNF-α as compared with the normal group. Results 
from previous studies showed that the level of MPO and TNF-α was 
increased with the seriousness of experimental colitis [20-21]. 
Previous studies suggested the significance of oxidative stress caused by 
reactive oxygen species (ROS) in the development of UC [20, 22]. In 
addition, NADPH oxidase enzymes, including NADPH oxidase 4 (NOX4), 
neutrophil cytosol factor 1 (p47 phox), and Rac related c3 botulinum 
toxin substrate 1(Rac1) are the main producers of ROS [23, 24]. ROS 
Overproduction via NADPH oxidase has been implicated in tissue 
damage observed in chronic inflammatory disorders [25] and plays 
critical roles in diverse biological processes, including host defense, cell 
growth and differentiation, proinflammatory genes activation, and cell 
death [26]. In the current research, the DSS injury was vastly higher than 
in the normal group, whereas sulfasalazine treatment significantly 
reduced the damage by DSS [9]. 
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Serum TFF3 was substantially increased in patients compared to 
healthy volunteers. Serum TFF3 levels were also significantly higher 
in patients who had no mucosal healing than in those with mucosal 
healing. These findings emphasize the hypothesis that TFF3 levels 
are correlated with intestinal mucosal inflammation and increased 
with the mucosal damage presence [27]. Grønbaek et al. [28] found 
that serum TFF3 levels were correlated with disease activity indices 
in patients with UC and they noted a potential to decrease TFF-3 
levels with clinical improvement steroids therapy and these results 
support our study. In the research conducted by Grønbaek et al. [28], 
there were significant variations in quantitative peptide 
measurements among individuals, which the authors felt was a 
pitfall of using trefoil peptides as a biomarker.  
It is found that Sulfasalazine has a remarkable effect on decreasing 
DSS-induced secretion of proinflammatory cytokines in rats with 
colitis, in order to suppress inflammatory responses in intestinal 
epithelial cells. From our findings, it can be concluded that mRNA 
levels of HMGB1, NF-κB and MMP 3 as well as miRNA-31 in rats with 
DSS-induced colitis are increased, while those are reduced by oral 
administration of sulfasalazine. Consequently, sulfasalazine 
contributes to the reduction of proinflammatory cytokines levels. 
Additionally, NF-κB is known to be an important factor for activation 
of IBD in humans and colitis in animals [29]. Antisense 
oligonucleotides can actually inhibit disease activity in rats with 
colitis, suggesting that NF-κB plays an essential role in inflammatory 
response mediation [30].  
The results of our current research showed that relative to rats in 
the control group, the expression of HMGB1, NF-κB, TFF3 and MMP 
3 as well as miRNA-31 were increased. Recent findings have found 
the significant roles of miRNAs in immune regulation, especially 
their potential utility as a novel anti-inflammatory agent to treat 
inflammatory diseases [31, 32]. In the acute colitis model, mucosal 
inflammation can be managed by using an agent to block the 
pathway of NF-κB, which marks a positive attempt [33]. Similar 
experimental outcomes can also be obtained, which are that 
sulfasalazine treatment can block phosphorylation of IκB and 
nuclear translocation of NF-κB, indicating that sulfasalazine inhibits 
the NF-κB signal pathway [33]. 
CONCLUSION 
Our study suggested that prior and concomitant administration of 
Sulfasalazine ahead of DSS significantly improved morphological, 
biochemical and histological features of ulcerative colitis. The anti-
inflammatory action of Sulfasalazine is due to the decrease of 
inflammatory mediators TNF-α, MPO and LRG and down regulation 
of HMGB1, NF-KB, MMB3, TFF3 and miRNA31 genes and increase of 
anti-inflammatory molecule cAMP. Further studies are warranted to 
identify other molecular mechanisms concerning Sulfasalazine. 
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